PATH | VRL
Menu

Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo-Controlled, Randomized Double-Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine

This article, published in PLOS ONE, reports on the results of a double-blinded, randomized, placebo-controlled Phase 1 clinical trial of a cold-adapted and temperature-sensitive A/H7N3 live attenuated influenza vaccine candidate. The results of the study determined that the vaccine was safe and well tolerated, immunogenic in healthy seronegative adults, and elicited the production of antibodies broadly reactive against the newly emerged A/H7N9 avian influenza virus.

Author: Rudenko L, Kiseleva I, Naykhin AN, et al.

Published: 2014

» Visit web page (English)

(Located at www.plosone.org)

Citation: Rudenko L, Kiseleva I, Naykhin AN, et al. Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo-Controlled, Randomized Double-Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine. PLOS ONE. 2014;9(2):e87962.

Resource types: Peer-reviewed journal

Diseases/vaccines: Influenza

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Eastern Europe